| First Author | Fu Y | Year | 2022 |
| Journal | FEBS Lett | Volume | 596 |
| Issue | 4 | Pages | 427-436 |
| PubMed ID | 34939667 | Mgi Jnum | J:322169 |
| Mgi Id | MGI:7256984 | Doi | 10.1002/1873-3468.14266 |
| Citation | Fu Y, et al. (2022) IL-17RD/sef exacerbates experimental mouse colitis and inflammation-associated tumorigenesis by regulating the proportion of T cell subsets. FEBS Lett 596(4):427-436 |
| abstractText | T helper cells, especially Th1 and Th17 cells, were reported to play a pivotal role in the pathogenesis of inflammatory bowel disease (IBD). However, the underlying factors regulating T cell functions in IBD progression remain to be fully elucidated. Here, we revealed that IL-17RD/Sef exacerbates DSS-induced colitis by regulating the balance of T cell subsets and their secretion of associated cytokines. We also observed that IL-17RD/Sef promotes colitis-associated tumorigenesis and negatively correlates with survival in both mouse and colorectal cancer patients. Our results suggested that IL-17RD/Sef functions as a regulator of T cell subsets to promote the inflammatory responses in the pathogenesis of IBD and colitis-associated colon cancer. |
